Despite advancements in cardiac transplant therapies, rejection remains a significant issue. Lovastatin, a statin drug with promising immunomodulatory effects, has garnered attention as a potential treatment for heart transplant rejection. Studies collectively highlight lovastatin's ability to influence T-cell activation, reduce acute rejection episodes, and maintain graft function. These findings offer promising avenues for enhancing transplant success rates and patient outcomes with the use of lovastatin. This survey aimed to explore opinions on lovastatin's use in rejection management post-heart transplantation. Participants from diverse backgrounds were surveyed on lovastatin's candidacy, perceived risks of non-approved drugs, and dyslipidemia prophylaxis importance. Analysis of 39 respondents revealed demographic trends, predominantly female (59%) and aged 18-24 (82.1%), primarily from Maryland and Virginia. Most had prior employment, with many in pharmacy-related roles, and held a 4-year degree as their highest education level. While 70.3% recognized lovastatin as a statin, opinions on its efficacy varied. Notably, 51.4% believed it should be considered for rejection management. Demographic comparisons showed significant differences in opinions, such as age groups differing in lovastatin's suitability (p = 0.003) and awareness of unapproved medications (p < 0.001). The study underscores diverse perspectives on lovastatin's efficacy for heart transplant rejection, emphasizing the need for further investigation. Patient education and dyslipidemia prevention are recognized as crucial for transplant survival. Given the array of viewpoints, more research is warranted to elucidate lovastatin's safety and effectiveness in this context.
IJPRAS
